Logo image of RAPT

RAPT THERAPEUTICS INC (RAPT) Stock Fundamental Analysis

NASDAQ:RAPT - US75382E1091 - Common Stock

11.38 USD
-0.08 (-0.7%)
Last: 8/29/2025, 8:00:01 PM
11.38 USD
0 (0%)
After Hours: 8/29/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, RAPT scores 3 out of 10 in our fundamental rating. RAPT was compared to 542 industry peers in the Biotechnology industry. RAPT has a great financial health rating, but its profitability evaluates not so good. RAPT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RAPT had negative earnings in the past year.
In the past year RAPT has reported a negative cash flow from operations.
RAPT had negative earnings in each of the past 5 years.
RAPT had a negative operating cash flow in each of the past 5 years.
RAPT Yearly Net Income VS EBIT VS OCF VS FCFRAPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

RAPT has a Return On Assets (-59.69%) which is in line with its industry peers.
RAPT has a better Return On Equity (-64.77%) than 60.48% of its industry peers.
Industry RankSector Rank
ROA -59.69%
ROE -64.77%
ROIC N/A
ROA(3y)-50.99%
ROA(5y)-46.45%
ROE(3y)-60.69%
ROE(5y)-53.99%
ROIC(3y)N/A
ROIC(5y)N/A
RAPT Yearly ROA, ROE, ROICRAPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

RAPT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RAPT Yearly Profit, Operating, Gross MarginsRAPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for RAPT has been increased compared to 1 year ago.
Compared to 5 years ago, RAPT has more shares outstanding
RAPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RAPT Yearly Shares OutstandingRAPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
RAPT Yearly Total Debt VS Total AssetsRAPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

RAPT has an Altman-Z score of 1.95. This is not the best score and indicates that RAPT is in the grey zone with still only limited risk for bankruptcy at the moment.
RAPT's Altman-Z score of 1.95 is fine compared to the rest of the industry. RAPT outperforms 69.12% of its industry peers.
RAPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.95
ROIC/WACCN/A
WACCN/A
RAPT Yearly LT Debt VS Equity VS FCFRAPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

RAPT has a Current Ratio of 13.25. This indicates that RAPT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 13.25, RAPT belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
RAPT has a Quick Ratio of 13.25. This indicates that RAPT is financially healthy and has no problem in meeting its short term obligations.
RAPT has a Quick ratio of 13.25. This is amongst the best in the industry. RAPT outperforms 87.50% of its industry peers.
Industry RankSector Rank
Current Ratio 13.25
Quick Ratio 13.25
RAPT Yearly Current Assets VS Current LiabilitesRAPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

RAPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.23%, which is quite impressive.
EPS 1Y (TTM)43.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RAPT will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.34% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y86.23%
EPS Next 2Y37.13%
EPS Next 3Y24.31%
EPS Next 5Y14.34%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RAPT Yearly Revenue VS EstimatesRAPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2029 2030 2031 2032 100M 200M 300M 400M 500M
RAPT Yearly EPS VS EstimatesRAPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RAPT. In the last year negative earnings were reported.
Also next year RAPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RAPT Price Earnings VS Forward Price EarningsRAPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RAPT Per share dataRAPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

RAPT's earnings are expected to grow with 24.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.13%
EPS Next 3Y24.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RAPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RAPT THERAPEUTICS INC

NASDAQ:RAPT (8/29/2025, 8:00:01 PM)

After market: 11.38 0 (0%)

11.38

-0.08 (-0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners76.34%
Inst Owner Change-86.97%
Ins Owners0.42%
Ins Owner Change0%
Market Cap188.23M
Analysts76.67
Price Target24.65 (116.61%)
Short Float %3.43%
Short Ratio2.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.36%
Min EPS beat(2)0.82%
Max EPS beat(2)41.9%
EPS beat(4)3
Avg EPS beat(4)-34.86%
Min EPS beat(4)-200.44%
Max EPS beat(4)41.9%
EPS beat(8)6
Avg EPS beat(8)-16.25%
EPS beat(12)9
Avg EPS beat(12)-9.2%
EPS beat(16)13
Avg EPS beat(16)-5.08%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.36%
PT rev (3m)383.33%
EPS NQ rev (1m)8.75%
EPS NQ rev (3m)-440.74%
EPS NY rev (1m)-19.25%
EPS NY rev (3m)-685.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.14
P/tB 1.14
EV/EBITDA N/A
EPS(TTM)-14.17
EYN/A
EPS(NY)-2.98
Fwd EYN/A
FCF(TTM)-5.57
FCFYN/A
OCF(TTM)-5.56
OCFYN/A
SpS0
BVpS9.94
TBVpS9.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.69%
ROE -64.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.99%
ROA(5y)-46.45%
ROE(3y)-60.69%
ROE(5y)-53.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.25
Quick Ratio 13.25
Altman-Z 1.95
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)61.2%
Cap/Depr(5y)59.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.56%
EPS Next Y86.23%
EPS Next 2Y37.13%
EPS Next 3Y24.31%
EPS Next 5Y14.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.04%
EBIT Next 3Y-4.7%
EBIT Next 5YN/A
FCF growth 1Y-4.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.23%
OCF growth 3YN/A
OCF growth 5YN/A